This post was originally published on this site
Closing yesterday’s session at $3.87, the stock is currently trading 30.4% below its 52-week high of $5.56.
Although SENS’ implantable Eversense CGM System to help patients manage their glucose levels holds promise, the application for the device is still under FDA review. So, it could take a while before the diabetes monitoring product starts generating revenues. Furthermore, the heavily shorted stock’s lofty valuation could make investors anxious.
